INTRODUCTION

Retroviral vectors represent an important tool in human gene therapy.
Although a wide variety of viral vectors have been developed, retroviral vectors (g and lentiviral) have been most widely used in gene therapy clinical trials to date, 1-3 as a result of their unique properties for the stable delivery of transgenes into target cells and the lack of immune reactivity. [4] [5] [6] Murine leukemia virus-based g-retroviral vectors have been used in a variety of gene therapy approaches. 7, 8 Unfortunately, the insertion of these and other viral vectors near cellular genes has been linked to their transcriptional activation, which may contribute to oncogenesis. [9] [10] [11] [12] [13] [14] The use of self-inactivating (SIN) g-retroviral vectors without enhancer-promoter sequences in the U3 region of the viral long terminal repeat (LTR) present several important advantages, the major ones being the increase of the internal promoter autonomy and a reduction of the risk of insertional upregulation of neighboring cellular genes. 15, 16 However, several types of murine leukemia virus g-retroviral SIN vectors were reported to yield lower viral vector titers, depending on the vector context. 17, 18 This has been associated to an abundant transcription from the internal promoter driving transgene expression, which may occur at the expense of full-length viral RNA transcription originating from the LTR in packaging cells. 18, 19 Various approaches were taken to overcome these limitations, such as the introduction of the post-transcriptional element from Woodchuck hepatitis virus into the 3¢-untranslated region of SIN vectors, 20, 17 or the incorporation of upstream polyadenylation enhancer elements derived from viral or cellular genes into the 3¢U3 region of the LTR, allowing partial recovery of high viral vector titers. 21 Recently, it has been observed that the use of a strong internal enhancer/promoter in SIN vectors may increase transgene expression but that this may also increase host cell transformation. 22, 23 Thus, despite recent progress showing high titers for some SIN vectors, 24 the production of high viral titers and the expression of the therapeutic gene at high levels without compromising safety may still remain a limitation for clinical use.
One approach to increase viral vector titer is to engineer the proviral vector plasmid with genetic elements that can increase the expression of the retroviral RNA without being incorporated into the final retroviral vector genome. 25 Various types of genetic boundary sequences or antisilencing elements have been used to protect proteincoding transgenes from chromatin-linked silencing effects and to increase protein expression. 26 For instance, the scaffold/matrix attachment regions (MARs) are thought to associate to the nuclear matrix, 27, 28 and to organize eukaryotic chromatin into independent loops. [29] [30] [31] [32] The establishment of independently regulated domains by loop formation has been proposed to insulate transgenes from negative effects of the genomic surroundings. 26, 29 Alternatively, MARs may boost the function of transcriptional enhancers, 29, [33] [34] [35] and they may act as origins of replication when transcribed. [36] [37] [38] [39] [40] Finally, MARs may mediate changes in the structure of the chromatin to increase the accessibility of the promoter region to allow an increase of transcription, and to mediate sustained expression by counteracting DNA methylation and by supporting histone acetylation. 29, 35, 41, 42 MAR elements have been previously shown to increase the stability and the expression of recombinant proteins from plasmids and viral vectors. 43, 44 We recently identified and characterized potent human MARs that increase and sustain elevated protein expression over prolonged cell culture time as a consequence of decreased variegation and silencing. 45, 46 In this study, we evaluated the performance of several human MAR elements to improve the viral production of SIN vectors. Two MAR elements were able to produce a significant increase in vector titer in the transient and in stable transfections. Thus, this approach may allow more efficient production of g-retroviral SIN vectors as a platform for the further optimizations of retroviral vector performance.
RESULTS
MAR elements improve the production of viral vector from transient transfections
To improve the yield of viral particles of g-retroviral SIN vectors produced from transfected HEK-293 cells, we initially evaluated several human MAR elements previously shown to increase and sustain transgene expression in CHO cells and in vivo. 45 We found that green fluorescent protein (GFP) expression plasmids containing MAR 1-68 (1-68M), 1-6 (1-6M) or X-29 (X-29M) could mediate increased expression in transient transfections, whereas 1-68M, 1-9M and X-29M were favorable in stable transfections (Supplementary Figure 1) . Subsequently, we positioned the most active MAR elements upstream of 5¢LTR promoter into the commercially available SIN retroviral vector pRetroQ-AcGFP1-C1, 47 so as to increase the expression of the viral vector RNA in producer cells without being incorporated in the final SIN-RV particles. These plasmid vectors contain the hybrid cytomegalovirus (CMV)/mouse sarcoma virus (MSV) enhancer/ promoter upstream of the R and U5 sequence of the 5¢ LTR sequence, the viral packaging signals, the GFP transgene driven by an internal CMV promoter and an antibiotic selection gene (Figure 1) .
Packaging HEK-293-derived cells were transfected transiently with MAR-containing plasmids and with the parental SIN-RV construct without MAR. To compensate for potential variations in the transfection efficiency, the GFP fluorescence was normalized to that of DsRed, as expressed from a cotransfected reference plasmid. An increase of both the number of fluorescent cells and the level of the GFP fluorescence were observed for plasmids containing 1-68M (Figures 2b and c) . Incorporating X-29M had no detectable effect, indicating that changes in plasmid size and/or structure cannot account for the gains observed on the insertion of 1-68M.
Cell culture supernatants containing the retroviral vectors were collected and used to transduce 208F cells to determine the vector titer. Packaging cells originally transfected with the 1-68M-containing plasmid yielded the highest retroviral vector titer, whereas a smaller but significant increase was also noted when using 1-6M (Figure 2d ). The number of infectious particles increased by two-or sixfold when comparing titers obtained from packaging cells generated with 1-6M or 1-68M-containing derivatives to that of the parental construct (Retro). This suggested that inclusion of the MARs may have increased the expression of the viral vector genomic RNA. This was assessed by measuring the viral RNA levels in packaging cells transfected with/without MAR using reverse transcription and quantitative PCR using primers targeting specifically the viral vector genomic RNA but not the transgene mRNAs (Figure 1) . The relative viral RNA levels obtained from packaging cells transfected with 1-6M or 1-68M were increased 8-or 16-fold in comparison with the MAR-devoid Retro vector (Figure 2d ). This indicated that the MAR element could increase the expression of the viral vector RNA, as may be expected from its location immediately upstream of the promoter that drives its synthesis.
To determine whether similarly favorable effects may also be obtained when using other transgenes and/or packaging cell lines, we extended our analysis to amphotropic packaging cells, which express envelope proteins capable of transducing human cells. Comparable increases in GFP transgene expression were obtained, resulting in a three-to sixfold increase in vector titer when using 1-6M and 1-68M (Supplementary Figure 2) . Expression of another transgene was assessed, namely the human secreted alkaline phosphatase (SEAP) in amphotropic packaging cells. SEAP RNA levels were augmented when using 1-68M in comparison with the Retro construct after transient and stable transfection of amphotropic cells, whereas smaller increases were detected with 1-6M (Supplementary Figure 3) . This indicated that 1-68M can increase the expression of the viral RNA using various types of transgene and packaging cells.
Sustained retroviral vectors production by MAR-containing polyclonal cell populations Stable polyclonal cell populations were selected to contain the proviral vector plasmid and an antibiotic resistance gene integrated into the cell genome. Analysis of GFP fluorescence indicated that the presence of the 1-68M or 1-6M yielded an increased expression of the transgene (Figures 3a and b) . Silencing of GFP expression was nearly completely abolished in presence of the MARs, whereas 56% of the cells generated without MAR had undetectable GFP fluorescence. Consequently, the occurrence of GFP-expressing cells was increased by approximately 2.5-fold in the presence of MAR (Figure 3c ). Normalized GFP expression levels were increased to a similar extent by MAR 1-6 and 1-68 ( Figure 3b ). Finally, twofold higher retroviral vector titers were obtained from polyclonal cell populations generated with MAR-containing plasmids as compared with packaging cells generated without MAR (Figure 3c ). This correlated with a prominent Figure 1 Schematic diagram illustrating the structure of retroviral vectors used in this study. The pRetroQ-transgene vector encodes puromycin-resistance gene and the GFP or the SEAP, as expressed from internal CMV and PGK promoters (dashed arrow), whereas the retroviral RNA is expressed from the hybrid (CMV/MSV) enhancer and promoter (P) fused to the g-retroviral 5¢LTR R and U5 sequences (long solid arrow). The U3 contains a SIN deletion that removes promoter elements while keeping the TATA box. In MAR-Retro-GFP vectors, different MAR (1-68M, 1-6M and X-29M) were incorporated upstream of 5¢LTR to augment retroviral vector RNA expression. MSV, murine sarcoma virus; PGK, phosphoglycerate kinase.
Improved retroviral vector production in gene therapy M Buceta et al increase of the viral vector RNA levels in populations generated with the MARs (Figure 3d ). This indicated that MAR elements may also contribute to maintain higher viral titers in stable populations, in agreement with their long-term antisilencing effects noted in other cell types. 46 The correlation between the retroviral vector titer and GFP expression was assessed on packaging cells sorted on the basis of moderate or high GFP fluorescence (Supplementary Figure 4) . Interestingly, the titer of infectious particles recovered from cell populations generated with the MARs was higher than that obtained from cells generated without MAR, although all populations were sorted to have similar levels of GFP fluorescence. For instance, the viral titer was increased more than fourfold by the 1-68M element relative to the control construct when comparing cell populations sorted to have high GFP expression. Thus, the MAR elements may have increased the expression of the viral RNA more than that of the GFP mRNA, as may be expected from its location immediately upstream of the promoter that drives the synthesis of the viral RNA. This also suggested that clones mediating high vector titers may be obtained more easily from these polyclonal populations. However, the finding that the viral RNA levels were increased much more than the viral titer also implied that the mere viral RNA level is not the sole determinant of vector titer.
1-68 MAR mediates high RV titers from packaging cell clones
Cell clones with different GFP expression levels were randomly isolated by the limiting dilution of polyclonal cell populations stably expressing the puromycin resistance gene on the transfected plasmid. Levels of GFP expression were recorded from six individual clones that were selected to show different GFP expression levels, as represented in the original polyclonal population. Flow cytometry analyses of clones generated with and without a MAR had variable degrees of GFP expression and heterogeneity (Figures 4a-c) . Clones generated with the 1-68M-containing plasmid showed higher GFP expression, and the heterogeneity of expression was often reduced (Supplementary  Table 1 ). Consistently, the viral titers were variable, but they were generally higher for clones generated using the plasmids containing either MAR element (Figures 4d-f ). On average, the GFP expression was increased 2.4-fold and the viral titer by 7.6-fold when comparing the six clones generated with 1-68M with the six control clones (Supplementary Table 2 ). Clones with medium or high levels of GFP expression often showed high viral vector titers. However, the correlation was not systematic, as some of the clones with the highest levels of GFP fluorescence yielded very low titers. No significant changes were observed in the average of the integrated copy numbers in clones with and without MAR. This indicated that other variables than the genomic locus of plasmid integration may also limit the viral vector titer, such as the competition between the internal and the upstream promoter, which may in turn affect viral RNA expression. Nevertheless, the use of 1-68M was clearly associated with a frequent occurrence of clones mediating higher viral titers, as most of the analyzed 1-68M-containing clones showed titers that were far above those reached with clones constructed without the MAR.
To better characterize the effect of MARs on the viral vector titer, we randomly picked three clones generated with or without a MAR and assessed the number of integrated trangene copies, the viral RNA level and the titer of infectious particles (Table 1) . As before, the average GFP expression and viral titer were strongly increased in MAR-containing clones, but there was little correlation between the Improved retroviral vector production in gene therapy M Buceta et al number of integrated GFP-coding sequences, GFP expression and viral titer when comparing individual clones. Although GFP expression levels were raised from 6-to 16-fold in MAR-containing clones, the viral RNA levels were increased by 32-or 38-fold, which translated to a 4.6-or 5-fold increase in vector titer when using 1-6M and 1-68M, respectively. Although the extent of the increase was not proportional, we noticed a strong correlation between the viral RNA level and the viral vector titer for all clones, whereas they were not correlated to the GFP expression. For instance, 1-68M-containing clones showing the highest levels GFP expression rather had moderately elevated viral titers. This may be explained by the known competition of internal and upstream promoters in the clones showing very high GFP expression. 48 
DISCUSSION
Although the transient generation of SIN vectors is relatively straightforward, the use of stably packaging cell lines to produce retrovirus derivatives as gene therapy delivery tools is often limited by cumbersome procedures to generate efficient cell lines, by relatively low titers of viral particles and/or by biosafety issues, with unfavorable practical and regulatory consequences for the production of clinical grade vectors. 49 Thus, strategies should be designed to increase vector titers without introducing regulatory sequences such as strong enhancer elements into the viral vector expression cassette. The objective of the present study was to assess whether epigenetic regulatory elements may be beneficial to generate SIN retroviral vectors. Several human MAR elements were introduced into the retroviral vector plasmid upstream of a chimerical 5¢LTR that drives the transcription of the retroviral vector RNA, and thus outside of the cassette encoding the RNA that is packaged in the viral particle. We found that the 1-68M is especially favorable in this setting, as it could improve the yield of retroviral vectors obtained from polyclonal populations of transiently transfected cells, whereas other MAR sequences yielded reduced or no benefit. This may be advantageous for the transient vector generation, as often performed in research and vector development.
1-68M was reported to stabilize the transcription of genes encoding therapeutic or indicator proteins in chinese hamster cell lines. 45, 46 It was also shown to prevent the irreversible silencing of an uninduced regulated transgene in mice muscles in vivo. 45 The present findings of a 1-68M-mediated increase of viral RNA expression and of the release of infectious viral particles, when taken together with these previous studies, indicate that this element may generally mediate increased transgene expression, irrespective of the cell origin and vector design, or whether a protein-coding mRNA or a viral genomic RNA is being expressed. However, an increase in transgene expression in transient studies had not been reported before with 1-68M, and the lack of effect in transient transfections is often used to distinguish enhancers from MAR elements. 45 Whether the positive effects seen in transient viral particle release may result from the use of human cells or from other particularities of the vector design is as yet unclear.
This study also shows that the use of MAR elements can facilitate the generation of cell populations that stably produce retroviral particles, as may be most favorable for the preparation of clinical grade vectors. We find that the MARs significantly decreased the occurrence of cells that release low or undetectable levels of vector, yielding for the most part cell clones that release vector titers that are up to 10-fold higher than those obtained without a MAR. Thus, in addition to increasing vector titer, the 1-68M may also obviate the need of lengthy isolation and analysis of numerous independent cell clones to identify one that mediates high and stable vector release. 
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The increase in protein expression elicited by MAR elements has been proposed to result from higher transgene transcription, as a result of more favorable chromatin structure and/or by directly increasing the transcription initiation rate. 35, 46 Alternatively, MARs have been shown to increase the genomic integration of transgenes in stable transfections. 45 The characterization of representative packaging cell clones indicated that the increased titer observed with the MAR did not result from more efficient plasmid integration in the genome of packaging cells but rather from an increased expression of the viral RNA. Interestingly, the MAR favored the expression of the viral RNA expressed from the promoter fused to the LTR to a greater extent than that of the transgene expressed from the internal CMV promoter. This likely resulted from the fact that MAR elements act most strongly when located immediately upstream of the target promoter and enhancer sequences. (Girod et al. 45 and unpublished results). However, this should not interfere with transgene expression in the final target cells, as the MAR and upstream promoter are no longer associated with the viral vector sequences in the final host cells.
We noticed during the course of this analysis that some of the packaging cells had a tendency to loose the ability to mediate higher vector titers upon culture. This effect was counteracted by selection for the expression of the antibiotic resistance gene associated with the coding sequences for the viral packaging proteins (data not shown). This finding may readily explain the strong increase of viral RNA expression by the MAR, whereas the increase of vector titer was less prominent, as the packaging proteins may become limiting at very Three randomly selected RV vector-producing HEK-293 cell clones were characterized in terms of the number of plasmid copies stably integrated in their genome, GFP expression (relative light units), the intracellular viral RNA level and the viral titer in the crude culture supernatant (infectious viral particles per ml). ***Po0.005 **Po0.05 and *Po0.5 versus the values of the clones generated without a MAR by the Student t-test.
high viral genomic RNA levels. Thus, the use of epigenetic elements that prevented viral RNA silencing may also be beneficial when constructing packaging cell lines. The approach taken in this study may therefore allow the optimization of both the plasmid vectors and of packaging cells that would release viral transcomplementing proteins more efficiently, complementing efforts to generate vectors with safer properties, whether from viral or non-viral origin.
MATERIALS AND METHODS Plasmids
Plasmids used to generate X29-MAR Retro, 1-6MAR Retro and 1-68MAR Retro populations and clones were derived from commercial pRetroQAcGFP1-C1, SIN-retroviral vector. This plasmid vector contains the hybrid CMV/mouse sarcoma virus enhancer/promoter upstream of 5¢ LTR sequence, the viral packaging signals, the GFP transgene driven by an internal CMV promoter and an antibiotic selection gene (Figure 1 ). pX29-MAR Retro, p1-6MAR Retro and p1-68MAR Retro plasmids were constructed by cloning 2152bp SmaI/EcoRV X29-MAR, 4582bp SmaI/EcoRV 1-6MAR and 3650bp Ecl136II/SmaI 1-68MAR inserts respectively in a 7615bp pRetroQ-AcGFP1-C1 vector digested by SspI, upstream of 5¢LTR. The cloning and characterization of the DNA sequence of these MAR elements has been reported previously (Genbank EF694965, EF694966 and EF694970). 45, 46 The SEAP coding sequence was subcloned by PCR from the pSEAP vector (Clontech Laboratory Inc., Mountain View, CA, USA) using the following primers: SpeI-SEAP forward, 5¢-GACTAGTCATGCTGCTGCTGCTGC-3¢ and BglII-SEAP reverse 5¢-GAAGATCTTGTCTGCTCGAAGCGGC-3¢. The pRetro-SEAP plasmid was obtained by exchanging the AcGFP1 sequence of pRetroQAcGFP1-C1 by the SEAP sequence after digestion with SpeI and BglII. p1-6MAR Retro-SEAP and p1-68MAR Retro-SEAP plasmids were constructed by cloning 5551bp SEAP containing fragment from AscI/SfiI digested pRetro-SEAP into AscI/SfiI digested p1-6MAR Retro-AcGFP and p1-68MAR RetroAcGFP vectors. More detailed information about plasmid construction may be available on request.
Cell lines and transfections
Ecopack and Amphopack packaging cell lines derived from human embryo kidney HEK293 cells were used for retroviral vector production as described by the provider (EcoPack2-293 and AmphoPack-293; Clontech Laboratories Inc.). Both cell types were maintained in Dulbecco's modified Eagle's medium (Glutamax, Invitrogen Life Technologies, Carlsbad, CA, USA), supplemented with 10% fetal bovine serum (Invitrogen Life Technologies) and 100 U ml À1 penicillin/streptomycin at 37 1C under 5% CO2.
Cells were replated 1 day before transfection into six-well plates. The culture medium was changed 3 h before transfection. A volume of 10 mg of the SIN pro-viral plasmid pRetroQ-AcGFP1-C or of the derivative vectors were transfected using calcium phosphate precipitation methods, as described by the plasmid manufacturer (Clontech Laboratories Inc.). To normalize for transfection efficiency variations, a DsRed plasmid was cotransfected as a control. The medium was changed 10-12 h after transfection. The supernatants containing the viral particles were collected 48 h after a change of the cell culture medium, cells and cell debris were removed by passage through a 0.22 mm filter, and they were stored at 4 1C until use. Titer determination was performed on 208F rat fibroblasts maintained in Dulbecco's modified Eagle's medium (Invitrogen Life Technologies) supplemented with 10% fetal bovine serum (Invitrogen Life Technologies) and 100 U ml À1 penicillin/streptomycin.
Generation of viral vector producer cells and titer determination
For the generation of stable producer cell populations, packaging cells were transfected with pRetroQ-AcGFP1-C1 and derivative vectors, and selected in complete medium containing 1.5 mg ml À1 puromycin (Invitrogen Life Technologies) and 1.5 mg ml À1 hygromycin for 3 weeks. Fluorescence-activated cell sorting of high and low GFP-expressing cells was performed on cells treated with trypsin and washed with PBS containing 5% fetal bovine serum. Single sorted cells were cultured in conditioned medium containing hygromycin and puromycin as above. Cell clones were generated by limiting dilution and expanded from randomly selected single cells.
For each vector construct, the titer was determined from unconcentrated culture supernatants of packaging HEK293 derivatives seeded into six-well plates (2Â106 cells per well) and incubated over night. The next day, cells were covered with 2 ml of fresh medium, and 208F indicator cells were seeded into six-well plates (5Â104 cells per well). After 12 h, a volume of 2 ml of serial dilutions of the filtered (0.45 mm; Millipore, Zug, Switzerland) culture supernatant of viral vector producer cells was added to the indicator cells. Polybrene (Sigma-Aldrich, Taufkirchen Germany) was added to a final concentration of 10 mg ml À1 . Transduced cells were cultivated for 48 h before quantifying the GFP-expressing transduced cells by cytofluorometry. The viral titer (number of infectious viral particles) was determined on 208F cells.
Generation of SEAP producer cells
AmphoPack-293 cells (Clontech Laboratories Inc.) were replated 1 day before transfection into six-well plates. At 3 h before transfection, the medium was exchanged and 10 mg of the SIN vectors pRetroQ-SEAP and p1-68MAR-RetroQ-SEAP and p1-6MAR RetroQ-SEAP were transfected using calcium phosphate precipitation methods, as indicated by the plasmid manufacturer (Clontech Laboratories Inc.). The medium was changed 8 h after transfection. The culture medium containing the SEAP (a secreted form of human alkaline phosphatase) was collected 48 h after a change of the cell culture medium. Packaging cell populations were transfected with pRetroQ-SEAP and derivative vectors and selection in complete medium containing 1.5 mg ml À1 puromycin (Invitrogen Life Technologies) for 2 weeks.
The expression of SEAP was detected using the Great EscAPe SEAP Chemiluminescence kit 2.0 (Clontech Laboratory Inc.). The supernatants obtained from packaging cells transfected with pRetroQ-SEAP and derivative vectors were analyzed 48 h after transfection or after 15 days of selection as indicated by the manufacturer (Clontech Laboratories Inc.).
Real time PCR analysis of transgene copy number and viral RNA levels Total genomic DNA for each clone was extracted using the DNeasy Tissue Kit (Qiagen, Hilden, Germany) following the manufacturer's instructions. Total DNA was resuspended in water, and the concentration of each sample was determined from absorbances at 260 nm using the NanoDrop ND-1000 spectrophotometer (Witec AG, Littau, Switzerland). Real-time quantitative PCR was performed using fluorescence dye SYBR green I, and each sample was analyzed in triplicate as described previously. 50 The following primers were used: GFP (forward, 5¢-ACATTATGCCGGACAAAGCC-3¢; reverse, 5¢-TTGTTT GGTAATGATCAGCAAGTTG-3¢) and the housekeeping GAPDH gene (forward primer, 5¢-CGACCCCTTCATTGACCTC-3¢; reverse primer, 5¢-CTCCACGACA TACTCAGCACC-3¢). The number of GFP transgenes integrated for each clone was estimated using the conserved housekeeping gene GAPDH as an internal reference.
Total RNA was isolated using the Rneasy Mini Kit as recommended by the manufacturer (Qiagen, Hilden, Germany) and 1 mg of total RNA was treated with DNase I (New England Biolabs, Ipswich, MA, USA) at 37 1C for 10 min to eliminate any potential interference by residual contaminating DNA followed by heat inactivation at 75 1C for 10 min. The total RNA was reverse transcribed to complementary DNA with the First-Strand cDNA Synthesis Kit (GE Healthcare, Buckinghamshire, UK) following the manufacturer's instructions. Complementary DNA was dituted 200-fold in water and 3.5 ml of the reverse transcribed samples were added to 15 ml PCR reactions. PCRs were performed in the LightCycler 480 System (Roche Diagnostics, Manheim, Germany) using LightCycler 480 SYBR Green I Master Mix (Roche) as described by the manufacturer. Specific primers were designed from the pRetro-GFP and pRetro-SEAP vectors to distinguish the full-length viral RNA from the shorter transgene mRNAs from pRetro-GFP transfected cells (forward primer, 5¢-TTTAGTGAACCGTCAGATCCG-3¢; reverse primer, 5¢-CATTCACATCGCCATTCAGC-3¢) and viral RNA from pRetro-SEAP transfected cells (forward primer, 5¢-TTTAGTGAACCGTCAGATCCG-3¢; reverse primer, 5¢-GTTCCAGAAGTCCGGGTTC-3¢). The eukaryotic translation elongation factor 1 a-1 (EEF1A1) mRNA was used as an endogenous reference using the following primers: (EEF1A1 forward, 5¢-TCCACTTGGTCGCTT TGCT-3¢; EEF1A1 reverse, 5¢-CTTCTTGTCCACAGCTTTGATGA-3¢). Specificity of the PCR was insured by performing reactions without reverse transcriptase or without template. Melting curves were performed to ensure the specificity and identity of the PCR products.
Accession numbers of the MAR sequences. Genbank: EF694965, EF694966 and EF694970.
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